Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash(The University of Texas MD Anderson Cancer Center), Michael A. Curran(The University of Texas MD Anderson Cancer Center)
Cited by 390
Related Papers
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
|Journal for ImmunoTherapy of Cancer|2018|286
Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia
|Cancer Research Communications|2024|4